Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
The price of Edgewise Therapeutics Inc (NASDAQ: EWTX) closed at $13.52 in the last session, down -1.64% from day before closing price of $13.74. In other words, the price has decreased by -$1.64 from its previous closing price. On the day, 0.52 million shares were traded. EWTX stock price reached its highest trading level at $13.59 during the session, while it also had its lowest trading level at $12.94.
Ratios:
We take a closer look at EWTX’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 20.99 and its Current Ratio is at 20.99. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Raymond James on July 30, 2025, initiated with a Strong Buy rating and assigned the stock a target price of $46.
On June 30, 2025, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $42.
On April 30, 2025, Guggenheim started tracking the stock assigning a Buy rating and target price of $41.Guggenheim initiated its Buy rating on April 30, 2025, with a $41 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on May 02 ’25 when Russell Alan J sold 1,551 shares for $16.45 per share. The transaction valued at 25,520 led to the insider holds 18,521 shares of the business.
MOORE JOHN R sold 1,930 shares of EWTX for $31,757 on May 02 ’25. The General Counsel now owns 6,531 shares after completing the transaction at $16.45 per share. On May 02 ’25, another insider, KOCH KEVIN, who serves as the President and CEO of the company, sold 4,276 shares for $16.45 each. As a result, the insider received 70,358 and left with 20,619 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, EWTX now has a Market Capitalization of 1445456256 and an Enterprise Value of 989952000.
Stock Price History:
The Beta on a monthly basis for EWTX is 0.27, which has changed by -0.16522545 over the last 52 weeks, in comparison to a change of 0.19283521 over the same period for the S&P500. Over the past 52 weeks, EWTX has reached a high of $38.12, while it has fallen to a 52-week low of $10.60. The 50-Day Moving Average of the stock is -4.20%, while the 200-Day Moving Average is calculated to be -39.99%.
Shares Statistics:
According to the various share statistics, EWTX traded on average about 852.23K shares per day over the past 3-months and 684020 shares per day over the past 10 days. A total of 95.21M shares are outstanding, with a floating share count of 77.09M. Insiders hold about 26.72% of the company’s shares, while institutions hold 74.46% stake in the company. Shares short for EWTX as of 1752537600 were 11074084 with a Short Ratio of 12.99, compared to 1749772800 on 12531401. Therefore, it implies a Short% of Shares Outstanding of 11074084 and a Short% of Float of 12.36.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
A detailed examination of Edgewise Therapeutics Inc (EWTX) is currently in progress, with 12.0 analysts providing valuable insights into its market dynamics.The consensus estimate for the next quarter is -$0.44, with high estimates of -$0.39 and low estimates of -$0.5.
Analysts are recommending an EPS of between -$1.56 and -$1.95 for the fiscal current year, implying an average EPS of -$1.75. EPS for the following year is -$2.03, with 11.0 analysts recommending between -$1.44 and -$2.35.
